Skip to main content
DARE
NASDAQ Life Sciences

Dare Bioscience Q2 10-Q: Going Concern Doubt, Nasdaq Delisting Hearing Set for Late August

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.37
Mkt Cap
$20.522M
52W Low
$1.13
52W High
$3.78
52W Position info
21% above low
Off High info
64% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DARE sits 21% above its 52-week low of $1.13.

Summary

Dare Bioscience disclosed going concern doubt, a Nasdaq delisting hearing in late August, and FDA concerns about its Ovaprene trial design in its Q2 2026 10-Q.


Key Events · Earnings and Guidance · DARE

  • Going Concern Doubt

    Management states substantial doubt about the company's ability to continue as a going concern within 12 months from the issuance date, citing uncertain revenue timing and the need for additional capital.

  • Cash Position and Working Capital Deficit

    Cash and cash equivalents of $12.6 million as of June 30, 2026, all of which represented grant funds restricted to specific projects. Working capital deficit of approximately $0.2 million.

  • Nasdaq Delisting Hearing

    Hearing before the Nasdaq Hearing Panel scheduled for late August 2026 to address stockholders' equity deficiency. Delisting would substantially impair capital raising and trading liquidity.

  • FDA Ovaprene Protocol Caution

    FDA approved the protocol amendment to remove the 250-completer expectation but cautioned the modified study may not generate sufficient safety evidence to support a favorable premarket approval decision.


Analysis · DARE · Life Sciences

Dare Bioscience's Q2 2026 10-Q reveals substantial doubt about its ability to continue as a going concern within 12 months. Cash of $12.6 million is entirely restricted to grant-funded projects, leaving a working capital deficit of $0.2 million. The company faces a Nasdaq delisting hearing in late August 2026 after stockholders' equity fell below $2.5 million. The FDA approved an Ovaprene protocol amendment but cautioned it may not generate sufficient safety evidence for approval. These combined risks threaten the company's listing and its ability to fund operations.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DARE was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.13 to $3.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DARE - Latest Insights

DARE
Oct 06, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.844
Real-time Price: $0.620 info
Change: -$0.224 (-27%) info
Market Cap: $12.195M info
DARE
Oct 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8428
Real-time Price: $0.620 info
Change: -$0.2228 (-26%) info
Market Cap: $12.195M info
DARE
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.8074
Real-time Price: $0.620 info
Change: -$0.1874 (-23%) info
Market Cap: $12.195M info
DARE
Aug 26, 2026, 5:15 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $0.810
Real-time Price: $0.620 info
Change: -$0.190 (-23%) info
Market Cap: $12.195M info
DARE
Aug 17, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.900
Real-time Price: $0.620 info
Change: -$0.280 (-31%) info
Market Cap: $12.195M info